ArticleFrontiers in pharmacology2021
Biotechnologically Produced
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- The JAK/STAT pathway: a pivotal therapeutic target in disease and advances in natural product modulation.Molecular diversity · 2026Review
- Lavandin cell extract enriched in rosmarinic acid attenuates inflammation via AMPK/Nrf2/HO-1 activation and IKK/IκB/NF-κB inhibition.BMC plant biology · 2026Article
- Plant Extracts Downregulating the JAK/STAT Signaling Pathway as a Potential Tool for Psoriasis Management: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Application ofPlants (Basel, Switzerland) · 2026Article
- Liposomal Delivery of a BiotechnologicalAntioxidants (Basel, Switzerland) · 2025Article
- Comprehensive disproportionality analysis of individual case safety reports associated with Janus kinase inhibitors in psoriasis and psoriatic arthritis using the FAERS database.Frontiers in immunology · 2025Article
- Review
- Development of Betulin-Loaded Nanostructured Lipid Carriers for the Management of Imiquimod-Induced Psoriasis.AAPS PharmSciTech · 2024Article
- Myconoside and Calceolarioside E Restrain UV-Induced Skin Photoaging by Activating NRF2-Mediated Defense Mechanisms.International journal of molecular sciences · 2024Article
- Large-Scale Production of Specialized Metabolites In Vitro Cultures.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Article
- Article
- Formulation and Testing of Antioxidant and Protective Effect of Hyalurosomes Loading Extract Rich in Rosmarinic Acid Biotechnologically Produced fromMolecules (Basel, Switzerland) · 2022Article
- Leucosceptoside A from Devil's Claw Modulates Psoriasis-like Inflammation via Suppression of the PI3K/AKT Signaling Pathway in Keratinocytes.Molecules (Basel, Switzerland) · 2021Article
- Hydroxycinnamic Acids and Derivatives Formulations for Skin Damages and Disorders: A Review.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a common skin pathology, characterized by dysregulation of epidermal keratinocyte function attended by persistent inflammation, suggesting that molecules with anti-inflammatory potential may be effective for its management. Rosmarinic acid (RA) is a natural bioactive molecule known to have an anti-inflammatory potential. Here we examined the effect of biotechnologically produced cell suspension extract of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.